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Background
Whether rapid lowering of elevated blood pressure would improve the outcome in 
patients with intracerebral hemorrhage is not known.
Methods
We randomly assigned 2839 patients who had had a spontaneous intracerebral 
hemorrhage within the previous 6 hours and who had elevated systolic blood pressure 
to receive intensive treatment to lower their blood pressure (with a target systolic 
level of <140 mm Hg within 1 hour) or guideline-recommended treatment (with a 
target systolic level of <180 mm Hg) with the use of agents of the physician’s choosing. 
The primary outcome was death or major disability, which was defined as a score 
of 3 to 6 on the modified Rankin scale (in which a score of 0 indicates no symptoms, 
a score of 5 indicates severe disability, and a score of 6 indicates death) at 90 days. 
A prespecified ordinal analysis of the modified Rankin score was also performed. 
The rate of serious adverse events was compared between the two groups.
Results
Among the 2794 participants for whom the primary outcome could be determined, 
719 of 1382 participants (52.0%) receiving intensive treatment, as compared with 
785 of 1412 (55.6%) receiving guideline-recommended treatment, had a primary 
outcome event (odds ratio with intensive treatment, 0.87; 95% confidence interval 
[CI], 0.75 to 1.01; P = 0.06). The ordinal analysis showed significantly lower modi-
fied Rankin scores with intensive treatment (odds ratio for greater disability, 0.87; 
95% CI, 0.77 to 1.00; P = 0.04). Mortality was 11.9% in the group receiving intensive 
treatment and 12.0% in the group receiving guideline-recommended treatment. 
Nonfatal serious adverse events occurred in 23.3% and 23.6% of the patients in the 
two groups, respectively.
Conclusions
In patients with intracerebral hemorrhage, intensive lowering of blood pressure 
did not result in a significant reduction in the rate of the primary outcome of 
death or severe disability. An ordinal analysis of modified Rankin scores indi-
cated improved functional outcomes with intensive lowering of blood pressure. 
(Funded by the National Health and Medical Research Council of Australia; 
 INTERACT2 ClinicalTrials.gov number, NCT00716079.)
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A cute intracerebral hemorrhage, which is the least treatable form of stroke, affects more than 1 million people 
worldwide annually,1,2 with the outcome deter-
mined by the volume and growth of the underlying 
hematoma.3-5 Blood pressure often becomes ele-
vated after intracerebral hemorrhage,6 frequently 
reaching very high levels, and is a predictor of 
outcome.7-11 On the basis of the results of the 
pilot-phase study, Intensive Blood Pressure Re-
duction in Acute Cerebral Hemorrhage Trial 1 
(INTERACT1),12-14 we conducted the main-phase 
study, INTERACT2,15 to determine the safety and 
effectiveness of early intensive lowering of blood 
pressure in patients with intracerebral hemor-
rhage.
Me thods
Trial Design
INTERACT2 was an international, multicenter, 
prospective, randomized, open-treatment, blinded 
end-point trial. Details of the design have been 
published previously15,16 and are summarized in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org. In brief, we 
compared the effect of a management strategy 
targeting a lower systolic blood pressure within 
1 hour with the current guideline-recommended 
strategy, which targets a higher systolic blood 
pressure, in patients who had a systolic blood 
pressure between 150 and 220 mm Hg and who 
did not have a definite indication for or contra-
indication to blood-pressure–lowering treatment 
that could be commenced within 6 hours after 
the onset of spontaneous intracranial hemor-
rhage; the diagnosis of intracranial hemorrhage 
was confirmed by means of computed tomogra-
phy (CT) or magnetic resonance imaging (MRI). 
Patients were excluded if there was a structural 
cerebral cause for the intracerebral hemorrhage, 
if they were in a deep coma (defined as a score of 
3 to 5 on the Glasgow Coma Scale [GCS],17 in 
which scores range from 3 to 15, with lower 
scores indicating reduced levels of consciousness), 
if they had a massive hematoma with a poor 
prognosis, or if early surgery to evacuate the he-
matoma was planned. Written informed consent 
was obtained from each patient or legal surro-
gate (before randomization or as soon as possi-
ble afterward) in accordance with national regu-
lations.
Investigators entered baseline data into a da-
tabase associated with a secure Web-based ran-
domization system. The data were checked to 
confirm the eligibility of the patient, and several 
key clinical variables were recorded before the 
system assigned a participant to intensive or 
guideline-recommended management of blood 
pressure with the use of a minimization algo-
rithm to ensure that the groups were balanced 
with respect to country, hospital, and time (≤4 
hours vs. >4 hours) since the onset of the intra-
cerebral hemorrhage. In participants who were 
assigned to receive intensive treatment to lower 
their blood pressure (intensive-treatment group), 
intravenous treatment and therapy with oral 
agents were to be initiated according to pre-
specified treatment protocols that were based on 
the local availability of agents, with the goal of 
achieving a systolic blood-pressure level of less 
than 140 mm Hg within 1 hour after randomiza-
tion and of maintaining this level for the next 
7 days. In participants who were assigned to re-
ceive guideline-recommended treatment (stan-
dard-treatment group), blood-pressure–lowering 
treatment was to be administered if their systolic 
blood pressure was higher than 180 mm Hg; no 
lower level was stipulated.18-20 All participants 
were to receive oral antihypertensive agents (or 
topical nitrates) within 7 days (or at discharge 
from the hospital if that occurred before 7 days), 
even if the agents had to be administered 
through a nasogastric tube; combination treat-
ment with an angiotensin-converting–enzyme 
inhibitor and a diuretic was recommended if 
that treatment was not contraindicated and if no 
different drugs were specifically required, with 
the goal of achieving a systolic blood pressure of 
less than 140 mm Hg during follow-up for the 
prevention of recurrent stroke.
Assessments
Demographic and clinical characteristics were 
recorded at the time of enrollment. The severity 
of the stroke was assessed with the use of the 
GCS17 and the National Institutes of Health 
Stroke Scale21 (NIHSS, on which scores range 
from 0 to 42, with higher scores indicating a 
more severe neurologic deficit) at baseline, at 24 
hours, and at 7 days (or at the time of discharge, 
if that occurred before 7 days). Brain CT (or MRI) 
was performed according to standard techniques 
at baseline (to confirm the diagnosis) in all pa-
tients, and at 24±3 hours in a subgroup of pa-
tients who were being treated at sites at which 
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repeat scanning was either part of routine prac-
tice or approved for research. Participants were 
followed up in person or by telephone at 28 days 
and at 90 days by trained local staff who were 
unaware of the group assignments. Participants 
who did not receive the assigned treatment or who 
did not adhere to the protocol were followed up 
in full, and their data were included in the analy-
ses according to the intention-to-treat principle.
Outcome Measures
The primary outcome measure was the propor-
tion of participants with a poor outcome, defined 
as death or major disability. Major disability was 
defined as a score of 3 to 5 on the modified 
Rankin scale at 90 days after randomization. 
Scores on the modified Rankin scale range from 
0 to 6, with a score of 0 indicating no symptoms; 
a score of 5 indicating severe disability, confine-
ment to bed, or incontinence; and a score of 
6 indicating death. The protocol specified “death 
or severe disability in patients treated within 
4 hours of onset of intracranial hemorrhage” as 
the key secondary outcome.15 However, during 
the course of the trial, ordinal approaches to the 
analysis of the modified Rankin scores gained 
acceptance in stroke trials. Therefore, in the fi-
nal statistical analysis plan,16 which was written 
before the initiation of data analysis, the key sec-
ondary outcome was redefined as physical func-
tion across all seven levels of the modified 
Rankin scale, as determined with the use of an 
ordinal analysis.22
Other secondary outcomes were all-cause mor-
tality and cause-specific mortality (classified at 
a central location, according to the definitions 
provided in the Supplementary Appendix, by in-
dependent adjudication experts who reviewed 
submitted medical documents); five dimensions 
of health-related quality of life (mobility, self-
care, usual activities, pain or discomfort, and 
anxiety or depression), as assessed with the use 
of the European Quality of Life–5 Dimensions 
(EQ-5D) questionnaire,23 with each dimension 
graded according to one of three levels of sever-
ity (no problems, moderate problems, or extreme 
problems); the duration of the initial hospital-
ization; residence in a residential care facility at 
90 days; poor outcomes at 7 days and at 28 days; 
and serious adverse events. The health statuses 
from each subscale of the EQ-5D were trans-
formed into a single utility value as a fraction of 
1 (with 0 representing death and 1 representing 
perfect health), with the use of population-based 
preference weights for the United Kingdom.24
The safety outcomes of primary interest were 
early neurologic deterioration (defined as an 
increase from baseline to 24 hours of 4 or more 
points on the NIHSS or a decrease of 2 or more 
points on the GCS) and episodes of severe hypo-
tension with clinical consequences that required 
corrective therapy with intravenous fluids or 
vasopressor agents. The difference in the vol-
ume of the hematoma from baseline to 24 hours 
was assessed in a prespecified subgroup of par-
ticipants who underwent repeat brain imaging.
Study Oversight
The study was conceived and designed by the ex-
ecutive committee (see the Supplementary Appen-
dix), whose members, along with selected principal 
investigators from various countries, developed 
the protocol (which is available at NEJM.org) and 
conducted the study. The study was approved by 
the ethics committee at each participating site. 
The corresponding author wrote the first draft of 
the manuscript, and other authors provided in-
put. All the authors made the decision to submit 
the manuscript for publication. Experienced re-
search staff monitored the study for quality and 
for the integrity of the accumulation of clinical 
data according to the study protocol. Monitoring 
for serious adverse events was performed routine-
ly, and any events that occurred were confirmed 
according to regulatory and Good Clinical Prac-
tice requirements, as outlined in the Supplemen-
tary Appendix. There was no commercial support 
for the study. Study data were collected, moni-
tored, and analyzed by the INTERACT2 Project 
Office and by statisticians at the George Institute 
for Global Health, who vouch for the accuracy 
and completeness of the data and the fidelity of 
the study to the protocol.
Statistical Analysis
We estimated that with a sample of 2800 partici-
pants, the study would have at least 90% power 
to detect a 14% relative reduction (a difference of 
7 percentage points) in the primary outcome, from 
50% in the standard-treatment group to 43% in 
the intensive-treatment group, assuming a between-
group difference in systolic blood pressure of 
13 mm Hg, a rate of nonadherence to treatment 
of 10%, and an overall loss to follow-up of 3%, 
with a type I error rate of 5% and with the use of 
a two-sided significance test. The data were ana-
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lyzed with the use of SAS software, version 9.2, 
according to the intention-to-treat principle.16
The primary analysis of the effect of treat-
ment on the primary outcome was unadjusted 
and is reported as an odds ratio with associated 
95% confidence intervals. We tested for signifi-
cance using a standard chi-square test of pro-
portions (with a two-sided alpha level of 5%). 
The scores on the modified Rankin scale were 
also analyzed with the use of an unadjusted 
proportional-odds regression model across all 
levels of the scale, after we checked that the as-
sumption of a common proportional odds was 
not violated.25 For sensitivity purposes, the pri-
mary outcome was analyzed after adjustment for 
randomization strata and prognostic baseline 
variables (age, region, NIHSS score, time from 
onset of the intracranial hemorrhage to random-
Table 1. Baseline Characteristics of the Participants.*
Characteristic
Intensive
Blood-Pressure  
Lowering
(N = 1399)
Guideline- 
Recommended 
Blood-Pressure  
Lowering
(N = 1430)
Time from onset of ICH to randomization — hr
Median 3.7 3.7
Interquartile range 2.8–4.8 2.9–4.7
Age — yr 63.0±13.1 64.1±12.6
Male sex — no. (%) 898 (64.2) 882 (61.7)
Recruited from China — no. (%) 947 (67.7) 973 (68.0)
Blood pressure — mm Hg
Systolic 179±17 179±17
Diastolic 101±15 101±15
NIHSS score†
Median 10 11
Interquartile range 6–15 6–16
GCS score‡
Median 14 14
Interquartile range 12–15 12–15
History of hypertension — no./total no. (%) 1012/1398 (72.4) 1036/1428 (72.5)
Current use of antihypertensive drugs — no./total no. (%) 627/1398 (44.8) 647/1428 (45.3)
Prior intracerebral hemorrhage — no./total no. (%) 115/1398 (8.2) 114/1428 (8.0)
Prior ischemic or undifferentiated stroke — no./total no. (%) 157/1398 (11.2) 166/1428 (11.6)
Prior acute coronary event — no./total no. (%) 39/1398 (2.8) 42/1428 (2.9)
Diabetes mellitus — no./total no. (%) 155/1398 (11.1) 150/1428 (10.5)
Use of warfarin anticoagulation — no./total no. (%) 50/1398 (3.6) 31/1428 (2.2)
Use of aspirin or other antiplatelet agent — no./total no. (%) 123/1398 (8.8) 142/1428 (9.9)
Baseline hematoma volume — ml
Median 11 11
Interquartile range 6–19 6–20
Deep location of hematoma — no./total no. (%)§ 1084/1294 (83.8) 1098/1319 (83.2)
Left hemisphere site of hematoma — no./total no. (%) 644/1294 (49.8) 669/1319 (50.7)
Intraventricular extension of hemorrhage — no./total no. (%) 371/1294 (28.7) 369/1319 (28.0)
* There were no significant differences between the groups in any of the characteristics listed here. ICH denotes intra­
cerebral hemorrhage.
† Scores on the National Institutes of Health Stroke Scale (NIHSS) range from 0 (normal neurologic status) to 42 (coma 
with quadriplegia).
‡ Scores on the Glasgow Coma Scale (GCS) range from 15 (fully conscious) to 3 (deep coma).
§ Deep location refers to location in the basal ganglia or thalamus.
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ization, volume and location of the hematoma, 
and presence or absence of intraventricular hem-
orrhage). The primary outcome was also analyzed 
according to various alternative cutoff points on 
the modified Rankin scale that have been used 
previously: a score of 0, 1, 2, or 3 as compared 
with scores of 4, 5, and 6 grouped together26 
and a score of 0 or 1 as compared with a score 
of 2, 3, 4, 5, or 6.27
We assessed the heterogeneity of the treatment 
effect on the primary outcome in eight pre-
specified subgroups by adding an interaction 
term in an unadjusted logistic-regression model. 
The effects of treatment on relative and absolute 
changes in hematoma volume were assessed by 
means of an analysis of covariance. The baseline 
volume of the hematoma and the time from the 
onset of the intracerebral hemorrhage to the CT 
were included as covariates, since both predict 
hematoma growth.4 The relative change in hema-
Table 2. Treatment of Patients with Intracerebral Hemorrhage.
Variable
Intensive
Blood-Pressure 
Lowering
(N = 1399)
Guideline- 
Recommended 
Blood-Pressure 
Lowering
(N = 1430) P Value
Time from ICH to start of treatment — hr <0.001
Median 4.0 4.5
Interquartile range 2.9–5.1 3.0–7.0
Time from randomization to start of treatment — hr <0.001
Median 0.1 0.3
Interquartile range 0.0–0.39 0.0–2.8
Blood­pressure–lowering treatment during first 24 hr — no. (%)
Any intravenous treatment 1260 (90.1) 613 (42.9) <0.001
Use of a single intravenous agent 849 (60.7) 421 (29.4) <0.001
Type of intravenous agent used
Alpha­adrenergic antagonist, such as urapidil 454 (32.5) 191 (13.4)
Calcium­channel blocker, such as nicardipine or  
nimodipine
227 (16.2) 122 (8.5)
Combined alpha­ and beta­blocker, such as labetalol 202 (14.4) 83 (5.8)
Nitroglycerin 209 (14.9) 59 (4.1)
Diuretic, such as furosemide 174 (12.4) 94 (6.6)
Nitroprusside 169 (12.1) 28 (2.0)
Hydralazine 82 (5.9) 50 (3.5)
Other 85 (6.1) 44 (3.1)
Medical and surgical treatment during the first 7 days —  
no./total no. (%)
Intubation 96/1379 (7.0) 93/1400 (6.6) 0.74
Admission to an intensive care unit 532/1379 (38.6) 529/1400 (37.8) 0.67
Prophylactic treatment for deep­vein thrombosis 306/1379 (22.2) 304/1400 (21.7) 0.76
Compression stockings 147/1379 (10.7) 146/1400 (10.4) 0.84
Subcutaneous heparin 248/1379 (18.0) 245/1400 (17.5) 0.74
Use of intravenous mannitol 855/1379 (62.0) 864/1400 (61.7) 0.88
Hemostatic therapy* 57/1379 (4.1) 40/1400 (2.9) 0.07
Any surgical intervention 77/1379 (5.6) 77/1400 (5.5) 0.92
Evacuation or decompression of the hematoma 43/1379 (3.1) 38/1400 (2.7) 0.53
Insertion of a ventricular drain 41/1379 (3.0) 44/1400 (3.1) 0.80
Decision to withdraw active treatment and care 75/1379 (5.4) 46/1400 (3.3) 0.005
* Hemostatic therapy included the use of fresh­frozen plasma, vitamin K, and recombinant tissue factor VIIa.
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toma volume was log-transformed to remove 
skewness after the addition of the value 1.1 to 
eliminate negative values. The nominal level of 
significance for all analyses was P<0.048, since 
two interim analyses were performed in which 
the Haybittle–Peto efficacy stopping rule was 
used.16
R esult s
Study Population
From October 2008 through August 2012, a total 
of 2839 participants (mean age, 63.5 years; 62.9% 
men) were enrolled at 144 hospitals in 21 coun-
tries; 1403 participants were randomly assigned 
to receive early intensive treatment to lower their 
blood pressure, and 1436 were assigned to re-
ceive guideline-recommended treatment (Fig. S1 
in the Supplementary Appendix). The baseline 
characteristics were balanced between the two 
groups (Table 1). The primary outcome was de-
termined for 1382 of the participants (98.5%) in 
the intensive-treatment group and for 1412 (98.3%) 
in the standard-treatment group.
Blood-Pressure–Lowering Treatment  
and Achieved Blood-Pressure Levels
As shown in Table 2, the median time from the 
onset of the intracerebral hemorrhage to the ini-
tiation of intravenous treatment was shorter in the 
intensive-treatment group than in the standard-
therapy group (4.0 hours [interquartile range, 2.9 to 
5.1] vs. 4.5 hours [interquartile range, 3.0 to 7.0], 
P<0.001); the median time from randomization 
to the initiation of treatment was also shorter in 
the intensive-treatment group (6 minutes [inter-
Table 3. Primary, Secondary, and Safety Outcomes at 90 Days.*
Variable
Intensive
Blood-Pressure 
Lowering
(N = 1399)
Guideline-  
Recommended 
Blood-Pressure 
Lowering
(N = 1430)
Odds Ratio  
(95% CI) P Value
Primary outcome: death or major disability — no./total no. (%)† 719/1382 (52.0) 785/1412 (55.6) 0.87 (0.75–1.01) 0.06
Secondary outcomes
Score on the modified Rankin scale — no./total no. (%)‡ 0.87 (0.77–1.00) 0.04
0: No symptoms at all 112/1382 (8.1) 107/1412 (7.6)
1: No substantive disability despite symptoms 292/1382 (21.1) 254/1412 (18.0)
2: Slight disability 259/1382 (18.7) 266/1412 (18.8)
3: Moderate disability requiring some help 220/1382 (15.9) 234/1412 (16.6)
4: Moderate–severe disability requiring assistance with daily 
living
250/1382 (18.1) 268/1412 (19.0)
5: Severe disability, bed­bound and incontinent 83/1382 (6.0) 113/1412 (8.0)
6: Death by 90 days 166/1382 (12.0) 170/1412 (12.0)
Death — no./total no. (%) 166/1394 (11.9) 170/1421 (12.0) 0.99 (0.79–1.25) 0.96
Health­related quality of life§
Problems with mobility — no./total no. (%) 767/1203 (63.8) 821/1231 (66.7) 0.88 (0.74–1.04) 0.13
Problems with self­care — no./total no. (%) 563/1202 (46.8) 635/1230 (51.6) 0.83 (0.70–0.97) 0.02
Problems with usual activities — no./total no. (%) 731/1203 (60.8) 814/1231 (66.1) 0.79 (0.67–0.94) 0.006
Problems with pain or discomfort — no./total no. (%) 477/1197 (39.8) 552/1227 (45.0) 0.81 (0.69–0.95) 0.01
Problems with anxiety or depression — no./total no. (%) 406/1192 (34.1) 463/1220 (38.0) 0.84 (0.72–1.00) 0.05
Overall health utility score 0.60±0.39 0.55±0.40 0.002
Living in residential care facility — no./total no. (%) 108/1222 (8.8) 114/1248 (9.1) 0.96 (0.73–1.27) 0.80
Duration of initial hospitalization — days 0.43
Median 20 19
Interquartile range 12–35 11–33
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quartile range, 0 to 39] vs. 19 minutes [inter-
quartile range, 0 to 167]). More patients in the 
intensive-treatment group than in the standard-
treatment group received two or more intrave-
nous agents to lower their blood pressure (26.6% 
vs. 8.1%, P<0.001). The mean systolic blood-pres-
sure levels differed significantly between the two 
groups from 15 minutes to day 7 after random-
ization (Fig. S2 in the Supplementary Appendix); 
at 1 hour, the mean systolic blood pressure was 
150 mm Hg in the intensive-treatment group (with 
462 patients [33.4%] achieving the target blood 
pressure of <140 mm Hg) as compared with 
164 mm Hg in the standard-treatment group (a 
difference of 14 mm Hg, P<0.001). As shown in 
Table 2, there were no significant differences be-
tween the two groups with respect to other aspects 
of medical care during the 7 days after random-
ization, except that a decision to withdraw active 
treatment and care was made in the case of more 
participants in the intensive-treatment group than 
in the standard-treatment group (75 participants 
[5.4%] vs. 46 participants [3.3%], P = 0.005).
Clinical Outcomes and Serious Adverse Events
At 90 days, 719 of the participants (52.0%) in the 
intensive-treatment group, as compared with 785 
(55.6%) in the standard-treatment group, had a 
poor outcome (odds ratio with intensive treat-
ment, 0.87; 95% confidence interval [CI], 0.75 to 
1.01; P = 0.06) (Table 3). The ordinal analysis 
showed a significant favorable shift in the distri-
bution of scores on the modified Rankin scale 
with intensive blood-pressure–lowering treatment 
(pooled odds ratio for shift to higher modified 
Rankin score, 0.87; 95% CI, 0.77 to 1.00; P = 0.04) 
(Table 3, and Fig. S3 in the Supplementary Ap-
pendix). Adjusted analyses showed consistency in 
the treatment effect with respect to the primary 
and key secondary outcomes in logistic-regression 
Table 3. (Continued.)
Variable
Intensive
Blood-Pressure 
Lowering
(N = 1399)
Guideline-  
Recommended 
Blood-Pressure 
Lowering
(N = 1430)
Odds Ratio  
(95% CI) P Value
Safety outcomes — no./total no. (%)
Neurologic deterioration in first 24 hr¶ 198/1369 (14.5) 211/1395 (15.1) 0.95 (0.77–1.17) 0.62
Nonfatal serious adverse events‖ 326/1399 (23.3) 338/1430 (23.6) 0.92
Any neurologic deterioration from intracerebral  
hemorrhage**
47/1399 (3.4) 55/1430 (3.8) 0.49
Recurrent intracerebral hemorrhage 4/1399 (0.3) 4/1430 (0.3)
Ischemic or undifferentiated stroke 8/1399 (0.6) 8/1430 (0.6)
Acute coronary event 5/1399 (0.4) 5/1430 (0.3)
Other cardiovascular disease 22/1399 (1.6) 26/1430 (1.8)
Noncardiovascular disease 160/1399 (11.4) 152/1430 (10.6) 0.49
Severe hypotension†† 7/1399 (0.5) 8/1430 (0.6)
* Plus–minus values are means ±SD. All odds ratios are unadjusted.
† The modified Rankin scale evaluates global disability and functioning; scores range from 0 (no symptoms) to 6 (death); the primary out­
come of death or major disability was assessed as a score on the modified Rankin scale of 3 to 6 at 90 days. 
‡ The difference between the groups in scores across all seven levels of the modified Rankin scale was determined with the use of a logistic­
regression analysis of the ordinal data.
§ Possible responses in each domain were “no problems,” “moderate problems,” or “extreme problems”; for these analyses, the latter two 
levels were combined as “any problems.” The overall health utility score was calculated with the use of population norms from the United 
Kingdom.
¶ Neurologic deterioration was defined as an increase from baseline to 24 hours of 4 or more points on the National Institutes of Health 
Stroke Scale or a decline of 2 or more points on the Glasgow Coma Scale.
‖ Nonfatal serious adverse events included those that were life­threatening, required inpatient hospitalization or prolongation of an existing 
hospitalization, or resulted in disability or a medical or surgical intervention; a patient could have more than one event.
** This category includes clinician­reported neurologic deterioration in a patient with cerebral mass effect or extension of the hematoma.
†† Severe hypotension was defined as hypotension with clinical consequences (including acute renal failure) that required corrective therapy 
with intravenous fluids, vasopressors, or hemodialysis.
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models that included prognostic variables and 
various cutoff points on the modified Rankin 
scale (Table S1 in the Supplementary Appendix).
In the assessment of the five domains of the 
EQ-5D, participants in the intensive-treatment 
group reported fewer problems and had signifi-
cantly better overall health-related quality of life 
at 90 days than did those in the standard-thera-
py group (mean [±SD] utility score, 0.60±0.39 vs. 
0.55±0.40; P = 0.002) (Table 3).
The rate of death from any cause was similar 
in the intensive-treatment group and the stan-
dard-treatment group (11.9% and 12.0%, respec-
tively) (Table 3), as was the percentage of these 
deaths attributed to the direct effect of the intra-
cerebral hemorrhage (61.4% and 65.3%, respec-
tively). The effects of intensive lowering of blood 
pressure were consistent across all prespecified 
subgroups (Fig. 1). There were no significant 
differences between the two groups in any of the 
other outcomes studied. The numbers of serious 
adverse events, including episodes of severe hy-
potension (which occurred in <1% of the par-
ticipants), were also balanced between the two 
groups (Table 3).
Hematoma Outcomes
The prespecified subgroup of participants who 
underwent repeat brain imaging for an assess-
ment of the between-group difference in hema-
1.0 2.0
Guideline-
Recommended
Treatment
Better
Intensive
Treatment
Better
Age
<65 yr
≥65 yr
Region
China
Other
Time to randomization
<4 hr
≥4 hr
Baseline systolic blood pressure
<180 mm Hg
≥180 mm Hg
History of hypertension
Yes
No
Baseline NIHSS score
<15
≥15
Baseline hematoma volume
<15 ml
≥15 ml
Baseline hematoma location
Deep
Others
Total
Intensive
Treatment Odds Ratio (95% CI)
Guideline-
Recommended
TreatmentSubgroup
0.87 (0.71–1.06)
0.86 (0.73–1.02)
0.81 (0.63–1.05)
0.92 (0.63–1.34)
0.87 (0.75–1.01)
0.90 (0.73–1.10)
0.96 (0.67–1.40)
0.83 (0.70–0.99)
0.72 (0.54–0.95)
0.93 (0.78–1.11)
0.88 (0.70–1.09)
0.86 (0.70–1.05)
0.91 (0.75–1.10)
0.81 (0.65–1.02)
0.86 (0.65–1.14)
0.86 (0.72–1.03)
0.5
0.91 (0.72–1.15)
P Value for
Homogeneity
340 (43.3)
379 (63.6)
431 (45.8)
288 (65.5)
435 (54.3)
284 (48.9)
372 (50.0)
347 (54.4)
524 (52.5)
194 (50.7)
393 (39.8)
324 (82.9)
285 (39.3)
383 (69.1)
568 (53.1)
100 (47.6)
719 (52.0)
352 (46.7)
433 (65.7)
480 (49.6)
305 (68.7)
465 (56.7)
320 (54.1)
400 (53.8)
385 (57.6)
555 (54.3)
228 (58.9)
440 (44.3)
341 (83.4)
309 (42.0)
416 (73.4)
614 (56.9)
111 (49.8)
785 (55.6)
0.76
0.97
0.48
0.90
0.12
0.48
0.57
0.76
no. of events (%)
Figure 1. Effect of Early Intensive Blood-Pressure–Lowering Treatment on the Primary Outcome, According to Prespecified Subgroups.
The primary outcome of the study was death or major disability, defined as a score of 3 to 6 on the modified Rankin scale (in which a 
score of 0 indicates no symptoms, a score of 5 indicates severe disability, and a score of 6 indicates death) at 90 days. Each percentage is 
based on the number of people in that subgroup. The black squares represent point estimates (with the area of the square proportional to 
the number of events), and the horizontal lines represent 95% confidence intervals. The diamond incorporates the point estimate, repre­
sented by the vertical dashed line, as well as the 95% confidence intervals, of the overall effects within categories. Scores on the National 
Institutes of Health Stroke Scale (NIHSS) range from 0 (normal neurologic status) to 42 (coma with quadriplegia).
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toma growth from baseline to 24 hours consisted 
of 491 of the 1399 participants with 90-day out-
come data (35.1%) in the intensive-treatment 
group and 473 of the 1430 participants with 90-
day outcome data (33.1%) in the standard-treat-
ment group. The mean hematoma volumes were 
15.7±15.7 ml and 15.1±14.9 ml in the two groups, 
respectively, at baseline and 18.2±19.1 ml and 
20.6±24.9 ml, respectively, at 24 hours (Table S2 
and Fig. S4 in the Supplementary Appendix). The 
difference in hematoma growth between the 
groups in the 24 hours after baseline was not 
significant (relative difference, 4.5% [95% CI, 
−3.1 to 12.7; P = 0.27], and absolute difference, 
1.4 ml [95% CI, −0.6 to 3.4; P = 0.18], after adjust-
ment for prognostic variables).
Discussion
In this trial involving patients with intracranial 
hemorrhage, early intensive lowering of blood 
pressure, as compared with the more conserva-
tive level of blood-pressure control currently rec-
ommended in guidelines, did not result in a sig-
nificant reduction in the rate of the primary 
outcome of death or major disability. However, in 
an ordinal analysis of the primary outcome, in 
which the statistical power for assessing physical 
functioning was enhanced, there were signifi-
cantly better functional outcomes among pa-
tients assigned to intensive treatment to lower 
their blood pressure than among patients as-
signed to guideline-recommended treatment.22,28 
Furthermore, there was significantly better phys-
ical and psychological well-being among patients 
who received intensive treatment. These results 
are consistent with observational epidemiologic 
findings associating high blood-pressure levels 
with poor outcomes among patients with intra-
cerebral hemorrhage7-11 and indicate that early 
intensive lowering of blood pressure in this pa-
tient population is safe.
There was no clear evidence of heterogeneity 
in the effect of treatment in any prespecified 
subgroup — not even in the subgroup defined 
according to region (China vs. elsewhere). More-
over, there was no evidence of a significant effect 
modification according to a history or no his-
tory of hypertension — a finding that is relevant 
because it has been postulated that patients with 
hypertension have an upward shift in cerebral 
autoregulation and possibly an increased risk of 
cerebral ischemia related to intensive lowering 
of blood pressure.8 However, given the critical 
nature and rapid evolution of bleeding in the 
brain, a somewhat surprising finding was the 
absence of a significant difference in the effect 
of treatment between patients who underwent 
randomization early (within 4 hours after the 
intracerebral hemorrhage) and those who under-
went randomization later. This could reflect either 
the limited power of the subgroup analyses or 
true independence of the effect of the intervention 
from the time of initiation of treatment. Since 
early intensive lowering of blood pressure did not 
have a clear effect on reducing the growth of the 
hematoma, a key determinant of early death, 
there may be other mechanisms at play, such as 
neuroprotection or a reduction in edema, that 
result in the later positive clinical outcomes 
with this treatment. The ongoing Antihyper-
tensive Treatment of Acute Cerebral Hemorrhage 
(ATACH) II trial29 is expected to provide addi-
tional information on the role of intensive lower-
ing of blood pressure within 4.5 hours after the 
onset of a intracerebral hemorrhage, but future 
evaluations of the treatment in patients with intra-
cerebral hemorrhage that are conducted in the 
prehospital setting or at more extended periods 
after onset than were tested in INTERACT2 may 
be warranted.
The current trial has several strengths, includ-
ing the large sample size, central concealment of 
treatment assignments, and high rates of follow-
up and adherence to treatment. Furthermore, 
the collection of data on serious adverse events, 
including hypotension, ensured that any poten-
tial harms were reliably detected and quantified. 
In addition, the range of drug therapies used 
and of outcomes assessed in participants from a 
variety of hospitals in different countries en-
hances the generalizability of the final results.
Some limitations should also be noted. First, 
although the option to use a range of available 
drug therapies rather than a single agent was a 
strength of the study, it introduced complexity in 
assessing the ways in which the effects may have 
varied across different agents. Moreover, in the 
open (unblinded) assignment of interventions 
that led to earlier and more intensive, as com-
pared with less intensive, control of blood pres-
sure, the outcomes may have been confounded 
by differences in the management strategies that 
were used for the two groups after randomiza-
tion, other than those that were documented. 
Second, although we used established scales and 
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objective criteria, some bias may have been in-
troduced in the assessment of key outcomes. 
Third, the difference in the blood-pressure levels 
achieved between the two groups may have been 
attenuated by the use of an active-comparator 
control group and the concomitant use of addi-
tional agents with blood-pressure–lowering 
properties (e.g., mannitol) or hemostatic proper-
ties (e.g., recombinant tissue factor VIIa); if this 
is so, however, the magnitude of the benefit of 
early intensive blood-pressure–lowering treat-
ment could be greater in settings in which only 
the very highest levels of blood pressure are 
treated in the hyperacute phase of stroke.
In summary, early intensive lowering of blood 
pressure did not result in a significant reduction 
in the rate of the primary outcome of death or 
major disability, but an ordinal analysis of 
scores on the modified Rankin scale did suggest 
that intensive treatment improved functional 
outcomes. Intensive lowering of blood pressure 
was not associated with an increase in the rates 
of death or serious adverse events.
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